Ibn Sina Pharmaceutical
Ibn Sina Pharma announces 63% cash dividend, highest in 7 years
Ibn Sina’s consolidated earnings per share (EPS) was Tk 21.46, compared to Tk 19.38 the previous year, according to a disclosure on the Dhaka Stock Exchange (DSE)
IBN Sina Pharma's Q3 profits up 44%
IBN Sina Pharmaceutical Industry secured a 44 percent year-on-year rise in profit in the January-March period of fiscal year 2023-24, which it attributed to an aggressive marketing strategy and proactive support from the management.
Ibn Sina to invest Tk 10 crore in subsidiary firm
The Ibn Sina Pharmaceutical is going to invest Tk 10 crore in its subsidiary the Ibn Sina API Industry Ltd as part of its capital investment in order to purchase capital machineries, the company said today.
Ibn Sina Pharma announces 63% cash dividend, highest in 7 years
Ibn Sina’s consolidated earnings per share (EPS) was Tk 21.46, compared to Tk 19.38 the previous year, according to a disclosure on the Dhaka Stock Exchange (DSE)
IBN Sina Pharma's Q3 profits up 44%
IBN Sina Pharmaceutical Industry secured a 44 percent year-on-year rise in profit in the January-March period of fiscal year 2023-24, which it attributed to an aggressive marketing strategy and proactive support from the management.
Ibn Sina to invest Tk 10 crore in subsidiary firm
The Ibn Sina Pharmaceutical is going to invest Tk 10 crore in its subsidiary the Ibn Sina API Industry Ltd as part of its capital investment in order to purchase capital machineries, the company said today.